针对肠道病毒71型的新型重组融合蛋白类病毒颗粒疫苗研制及其免疫效果评价
Preparation and identification of a novel anti-Enterovirus 71 vaccine of recombinant fusion protein virus-like particle
目的 研制针对肠道病毒71型(EV71)的新型重组类病毒颗粒疫苗,并评价其免疫效果.方法 利用诺如病毒(NoV)衣壳蛋白(VP1)P区(NoVP)可呈现外源抗原并形成类病毒颗粒的特点,构建获得只包含NoVP或在其表面环位点串联插入EV71衣壳蛋白的三个特异性抗原位点(VP1的SP55和SP70,VP2的VP2-28)基因片段,克隆至质粒pET-28a(+)后分别转化大肠杆菌后诱导表达,通过十二烷基硫酸钠聚丙烯酰胺凝胶电泳(SDS-PAGE)、免疫印迹和透射电镜鉴定和观察表达的重组融合蛋白(NoVP+ EV71-SP55-SP70-VP2-28)和NoVP蛋白.同时,采用随机分组法将BALB/C小鼠分成A、B和C三组,每组10只,分别用重组融合蛋白(NoVP+ EV71-SP55-SP70-VP2-28)、NoVP和透析液免疫获得抗血清,采用酶联免疫吸附试验(ELISA)检测小鼠血清中特异性抗体;将小鼠血清与EV71 H3-TY株混合,加入Vero细胞,通过微量中和实验检测特异性抗体效价.采用方差分析和Bonferroni检验对数据进行分析.结果 重组表达产物在大肠杆菌中以包涵体形式存在,SDS-PAGE显示重组融合蛋白和NoVP相对分子质量约为43×103和36×103;免疫印迹显示重组融合蛋白在相对分子质量约为43×103处有特异性条带,透射电镜观察显示重组融合蛋白呈现类病毒颗粒.ELISA显示与SP70多肽反应的小鼠血清吸光度(A490)值A组明显大于B组和C组(F=13.860,P<0.05);微量中和实验显示A组小鼠血清针对EV71 H3-TY株的几何平均中和滴度为1∶38.结论 本研究初步获得了针对EV71的一种新型重组融合蛋白类病毒颗粒疫苗,其具有良好的抗原性和特异性,能诱导小鼠产生较高中和滴度的特异性抗体.
更多Objective To develop a novel anti-Enterovirus 71 (EV71) vaccine as recombinant virus-like particles.Methods By utilizing the foreign antigen presentation and virus-like particles forming features of Norovirus casipid VP1 P domain (NoVP), two pET-28a (+)-based recombinant expression plasmids containing either NoVP alone or NoVP with three specific epitopes SP55, SP70 and VP2-28 of EV71 capsid proteins tandemly inserted at the surface loop site were constructed and transferred to Escherichia coli.The recombinant fusion proteins of NoVP + EV71-SP55-SP70-VP2-28 and NoVP were induced expression and confirmed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), Western blot and transmission electron microscopy (TEM) observation.BALB/C mice were randomly divided into three groups:group A immunized with the recombinant fusion protein, group B immunized with NoVP and group C injected with 10 mmol/L Tris plus 20 mmol/L NaCl (pH 9.0).Enzymelinked immunosorbent assay (ELISA) was used to test specific antibodies in the serum of the mice, besides, the serums were mixed with the EV71 H3-TY strain and Vero cells, then specific antibody titer was examined by microneutralization test.One way ANOVA and Bonferroni test were used to analyze data.Results Both recombinant fusion protein and NoVP were expressed in Escherichia coli in inclusion bodies form.SDS-PAGE demonstrated that the relative molecular weights of recombinant fusion protein and NoVP protein were approximately 43 × 103 and 36 × 103, respectively;positive protein band of about 43 × 103 (relative molecular mass) was detected in recombinant fusion protein by Western Blot.Virus-like particles derived from the recombinant fusion proteins were observed under TEM.ELISA showed that absorbance 490 (A490) of mice serum added in SP70 peptide was significantly higher than those of group B and C (F =13.860,P <0.05).And microneutralization test demonstrated that the serum from group A was able to neutralize EV71 at a geometric mean titer above 1:38.Conclusion A novel virus-like particles vaccine against EV71 with good antigenicity and specificity has been prepared, which is able to induce high titer of neutralizing antibody against EV71 in mice.
More- 浏览:211
- 被引:0
- 下载:32
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文